Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology.

Fiche du document

Auteurs
Date

28 octobre 2020

Type de document
Périmètre
Langue
Identifiants
Source

Serveur académique Lausannois

Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3390/ijms21218021

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33126538

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1422-0067

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_44F221AEB60A2

Collection

Serveur Académique Lausannois

Organisation

Université de Lausanne et CHUV

Licences

info:eu-repo/semantics/openAccess , CC BY 4.0 , https://creativecommons.org/licenses/by/4.0/

Mots-clés 0

Amino Acid Sequence; Antineoplastic Agents/therapeutic use; Female; GTP-Binding Protein alpha Subunits, Gq-G11/chemistry; GTP-Binding Protein alpha Subunits, Gq-G11/genetics; GTP-Binding Protein alpha Subunits, Gq-G11/metabolism; Humans; Melanoma/drug therapy; Melanoma/genetics; Melanoma/metabolism; Melanoma/pathology; Middle Aged; Models, Molecular; Mutant Proteins/chemistry; Mutant Proteins/genetics; Mutant Proteins/metabolism; Mutation; Protein Conformation; Protein Stability; Pyridones/therapeutic use; Pyrimidinones/therapeutic use; Receptor, Fibroblast Growth Factor, Type 4/chemistry; Receptor, Fibroblast Growth Factor, Type 4/genetics; Receptor, Fibroblast Growth Factor, Type 4/metabolism; Sequence Homology; Signal Transduction; Uveal Neoplasms/drug therapy; Uveal Neoplasms/genetics; Uveal Neoplasms/metabolism; Uveal Neoplasms/pathology; FGFR4; GNAQ; molecular modelling; mutation; precision oncology

Sujets proches En

Modelmaking Modelling Model-making Molding (Clay, plaster, etc.) Clay modeling Modelling

Citer ce document

F.S. Krebs et al., « Trametinib Induces the Stabilization of a Dual GNAQ p.Gly48Leu- and FGFR4 p.Cys172Gly-Mutated Uveal Melanoma. The Role of Molecular Modelling in Personalized Oncology. », Serveur académique Lausannois, ID : 10.3390/ijms21218021

Métriques

Partage / Export

Résumé 0

We report a case of an uveal melanoma patient with GNAQ p.Gly48Leu who responded to MEK inhibition. At the time of the molecular analysis, the pathogenicity of the mutation was unknown. A tridimensional structural analysis showed that Gα q can adopt active and inactive conformations that lead to substantial changes, involving three important switch regions. Our molecular modelling study predicted that GNAQ p.Gly48Leu introduces new favorable interactions in its active conformation, whereas little or no impact is expected in its inactive form. This strongly suggests that GNAQ p.Gly48Leu is a possible tumor-activating driver mutation, consequently triggering the MEK pathway. In addition, we also found an FGFR4 p.Cys172Gly mutation, which was predicted by molecular modelling analysis to lead to a gain of function by impacting the Ig-like domain 2 folding, which is involved in FGF binding and increases the stability of the homodimer. Based on these analyses, the patient received the MEK inhibitor trametinib with a lasting clinical benefit. This work highlights the importance of molecular modelling for personalized oncology.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en